DeCure for Intellectual developmental disorder with abnormal behavior, microcephaly, and short stature
DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for intellectual developmental disorder with abnormal behavior, microcephaly, and short stature — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntellectual developmental disorder with abnormal behavior, microcephaly, and short stature maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intellectual developmental disorder with abnormal behavior, microcephaly, and short stature is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
pseudouridine synthase 7 (PUS7) — PUS7 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KKP · 2.26 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
No drug is tested or proposed in any of these three abstracts. The 2001 review argues that growth hormone therapy for short children without proven deficiency is cosmetic, not medical, and that the belief in psychosocial disadvantage from short stature rests on flawed, clinic-referred samples rather than population-based data. The 2024 Spanish case report describes two new male patients with a previously unreported USP27X gene variant causing X-linked intellectual developmental disorder, microcephaly, and digital anomalies; no treatment is discussed. The 2025 case report of a 12-year-old with KBG syndrome (ANKRD11 mutation) and ADHD describes his behavioural and learning difficulties but does not report any drug intervention or outcome.
Across the three abstracts, no drug is named, no response rate or survival figure is given, and no therapeutic trial is described. The only intervention mentioned is growth hormone, and the 2001 review explicitly states that for short but otherwise normal children it is cosmetic and raises ethical concerns. The genetic reports simply broaden the known phenotypic spectrum of two rare conditions.
What is missing is any clinical trial, any drug candidate, any biomarker for patient stratification, and any funding for treatment research in these specific genetic intellectual developmental disorders. The abstracts provide no evidence that any existing drug modifies the course of USP27X-related disorder or KBG syndrome.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Endocrinology and Metabolism · 2001 · 46 citations
Short Normal Stature and Psychosocial Disadvantage: A Critical Review of the Evidence
AbstractPhysicians and parents alike are under increasing pressure to identify and to treat short stature, but intervention implies the presence of some pathology, physical or psychological, that can be corrected. Where there is true GH deficiency, the argument for replacement is uncontroversial. It is less compelling where GH 'insufficiency' is diagnosed. In the case of the short, but otherwise normal, child the indications for therapy are even less clear. Short stature, per se, is clearly not a disease, in spite of the perception by some practitioners that the rate of growth of such children is abnormal. Short stature is, however, commonly perceived to be associated with social and psychological disadvantage, yet many of these misperceptions about short stature can be challenged. A critical review of the literature pertaining to the psychosocial correlates of short stature uncovers much flawed evidence. Most importantly, the belief, widely held by paediatricians, that short children are likely to be significantly disadvantaged, has been founded largely on data from clinic-referred samples. In such studies, children with real (or perceived) behavioural or academic problems are likely to be overly represented. Publications arising from such studies, however, inevitably lead to an increase in the demand for treatment both from and for those who previously had no such concern. In contrast, data from a well controlled, prospective population-based study suggest the essential normality of the short normal child. Parents and children alike should be reassured by these findings. In the absence of clear pathology, physical or psychological, GH therapy for short but otherwise normal children must therefore, in most cases, be deemed cosmetic, raising issues as to the ethics of so-called "plastic endocrinology".
Revista de Neurología · 2024 · 0 citations · open access
Dos nuevos casos de discapacidad intelectual ligada al cromosoma X tipo 105 por variante patógena en el gen USP27X no descrita previamente
AbstractINTRODUCTION: X-linked intellectual developmental disorder is clinically and genetically heterogeneous. The ubiquitin specific peptidase 27 X-linked gene (USP27X) has been associated with X-linked intellectual developmental disorder, and only 17 affected males have been described in the literature to date. CASE REPORT: A 6-year-old boy was assessed due to intellectual developmental disability, language delay, behavioural disorder, microcephaly and particular features. His mother had learning difficulties and a facial phenotypic overlap. A maternal uncle had an intellectual developmental disorder. Physical examination revealed an unusual phenotype (triangular facies, long palpebral fissures and eyelashes, medially eyebrow loss, prominent auricles), mild brachydactylia and hypoplasia in the distal phalanges. The clinical exome identified the probably pathogenic variant NM_001145073.3: c.692delT in the USP27X gene. The results of the family segregation analysis were positive: the mother and maternal uncle were harbourers, while healthy maternal aunt was not. CONCLUSIONS: We present two new cases of X-linked intellectual developmental disorder due to a previously unreported variant in the USP27X gene. Both patients presented neurological symptoms without any significant involvement at other levels, according to the literature. One of the cases presented microcephaly, particular features and digital anomalies, which broadens the phenotypic spectrum of this disease.
European Psychiatry · 2025 · 0 citations · open access
KBG syndrome: a case report of a 12-year-old male child with ADHD
AbstractIntroduction KBG syndrome is a rare genetic condition (autosomal dominant inheritance - ANKRD11 mutation) with a particular phenotype (short stature, craniofacial dysmorphism and skeletal abnormalities) and neurodevelopmental delay or intellectual disability. Patients with this condition usually have a greater tendency to present symptoms related to impulsivity and distractibility typical of ADHD, as well as behavioral disturbances and aggressiveness. We present the case of a 12-year-old male child who is being followed up at the Child and Adolescent Mental Health Department for intellectual disability and ADHD combined. Objectives To address the importance and multidisciplinary approach of the KBG Syndrome in the pediatric population with a diagnosis of ADHD based on the presentation of the aforementioned clinical case. Methods Bibliographic search and description of a clinical case of a patient under follow-up for Child and Adolescent Mental Health at the “Hospital Clínico Universitario de Valladolid”. Results A 12-year-old boy from Spain was referred to the Child and Adolescent Psychiatry Department for attention and concentration difficulties and impulsivity problems. The parents describe the patient as a restless and nervous child who is sometimes aggressive in moments of important frustration. They point out that he impulsively performs dangerous acts, such as crossing the road without making sure that a car is not coming by, and is easily distracted. The School Center reports that the child is incapable of following the rules and shows great difficulty in learning. He has a medical history of growth delay with problems of right dorsal scoliosis requiring the use of a night corset, moderate hypoacusis in the right ear, myopia and astigmastism and macrodontia. He also underwent surgery for epigastric hernia. In addition, he shows a particular phenotype that shares with his mother and for which genetic studies have been performed that determined the ANKRD11 mutation, confirming the diagnosis of KBG syndrome. Conclusions KBG syndrome is a rare genetic condition that should be considered in the differential diagnosis of patients with cognitive and behavioral difficulties in combination with a distinctive phenotype. The importance of the diagnosis of this entity lies in being able to offer a better multidisciplinary medical approach at the organic and mental health level. It is also important to be able to plan and propose an adapted education at school and to provide tools and management strategies to the family at home for a better prognosis and quality of life of the patient and his environment. Disclosure of Interest None Declared
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
